BridgeMD
New treatment option for Postherpetic Neuralgia
Official title Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia
ClinicalTrials.gov ID: NCT06896994
What this study is testing
What is esketamine group?
esketamine group is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for postherpetic neuralgia.
Also referred to as pregabalin+duloxetine+esketamine.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- To assess the 1-week effects and safety of esketamine in combination with pregabalin and duloxetine to relieve pain in patients with postherpetic Neuralgia(PHN).
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Ages more than 18 years;
- Pain present for more than 3 months after healing of a herpes zoster skin rash;
- Has an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0= no pain, 10= worst possible pain)；
- Failed to respond to or tolerate the effective dose of pregabalin monotherapy.
You likely can't join if
- Obstructive sleep apnoea syndrome;
- Those who receive treatment treatments;
- A history of systemic immune diseases, organ transplantation, or cancers;
- A history of severe cardiopulmonary, hepatic or renal dysfunction;
- A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;
- Currently using monoamine oxidase inhibitors (MAOIs);
See the full eligibility criteria
- Ages more than 18 years;
- Pain present for more than 3 months after healing of a herpes zoster skin rash;
- Has an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0= no pain, 10= worst possible pain)；
- Failed to respond to or tolerate the effective dose of pregabalin monotherapy.
- Obstructive sleep apnoea syndrome;
- Those who receive treatment treatments;
- A history of systemic immune diseases, organ transplantation, or cancers;
- A history of severe cardiopulmonary, hepatic or renal dysfunction;
- A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;
- Currently using monoamine oxidase inhibitors (MAOIs);
- Having untreated angle-closure glaucoma;
- Those suffering from increased intracranial pressure；
- Comorbid hyperthyroidism or phaeochromocytoma;
- Suspected or confirmed history of drug abuse;
- Having contraindications to esketamine, pregabaline or duloxetine;
- Communication difficulties;
- Women who are preparing for pregnancy, in the pregnancy or lactation period.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.